Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of sitagliptin-based vs liraglutide-based treatment in type 2 diabetes inadequately controlled on metformin
2010-023759-27Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2010
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sitagliptin and liraglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Merck & Co. Primary endpoint: Change in HbA1c from baseline at Week 26. Started Dec 2010; status: completed.
02
Drugs
sitagliptinliraglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2010-023759-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023759-27.